The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation.
 
Ligang Xing
No Relationships to Disclose
 
Gang Wu
No Relationships to Disclose
 
Lvhua Wang
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Jian-Cheng Li
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Jianhua Wang
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Zhiyong Yuan
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Ming Chen
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Yaping Xu
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Zhengfei Zhu
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
You Lu
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Chun Han
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Tingyi Xia
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Conghua Xie
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Guang Li
Research Funding - Shanghai Roche Pharmaceuticals (Inst)
 
Jinming Yu
No Relationships to Disclose